Study Comparing Nivolumab and Ipilimumab with Chemotherapy to Chemotherapy Alone for Patients with Stage IV Non-Small Cell Lung Cancer

3 1 1 1

What is this study about?

This clinical trial is focused on studying treatments for Stage IV Non-Small Cell Lung Cancer (NSCLC). The study is comparing the effectiveness of a combination of two medications, nivolumab and ipilimumab, along with chemotherapy, against chemotherapy alone. Nivolumab and ipilimumab are types of medications known as immunotherapies, which help the body’s immune system fight cancer. Chemotherapy is a common cancer treatment that uses drugs to kill cancer cells.

The purpose of this study is to see if the combination of nivolumab and ipilimumab with chemotherapy is more effective than chemotherapy alone for patients with Stage IV NSCLC. Participants in the study will receive either the combination treatment or chemotherapy by itself. The study will monitor the participants over time to assess the effectiveness of the treatments in terms of survival and response to the therapy.

Throughout the study, participants will receive their treatments through an intravenous (IV) infusion, which means the medication is given directly into a vein. The study aims to provide valuable information on whether adding nivolumab and ipilimumab to chemotherapy can improve outcomes for patients with advanced lung cancer. The trial is expected to continue until 2025, allowing researchers to gather comprehensive data on the long-term effects and benefits of the treatment combinations.

1 joining the study

Upon joining the study, the patient will be informed about the trial’s purpose, which is to compare the effectiveness of a combination of medications with standard chemotherapy in treating stage IV non-small cell lung cancer.

The patient will be required to provide consent to participate in the study.

2 initial assessment

An initial assessment will be conducted to confirm eligibility. This includes a pregnancy test for women of childbearing potential and discussions about contraception requirements for both men and women during and after the treatment period.

3 treatment phase

The treatment phase involves receiving medications through intravenous infusion. The medications include nivolumab, ipilimumab, and chemotherapy drugs such as paclitaxel, cisplatin, carboplatin, and pemetrexed.

The specific combination and schedule of these medications will be determined by the study protocol. The patient will receive these treatments as part of the study’s regimen.

4 monitoring and follow-up

Throughout the study, the patient’s health and response to treatment will be closely monitored. This includes regular check-ups and assessments to evaluate the effectiveness of the treatment and any side effects.

The study aims to measure outcomes such as overall survival and progression-free survival.

5 completion of the study

Upon completion of the treatment phase, the patient will undergo a final assessment to gather data on the treatment’s impact.

The study is expected to conclude by December 2025, at which point the collected data will be analyzed to determine the efficacy of the treatment combinations.

Who Can Join the Study?

Participants must have Stage IV Non-Small Cell Lung Cancer (NSCLC). This means the cancer has spread to other parts of the body.
Women who can have children must have a negative pregnancy test before starting the study medication. This test checks for a hormone called human chorionic gonadotropin (HCG), which is present during pregnancy.
Women who can have children must agree to use birth control while taking the study medication and for 5 months after the last dose. This is to prevent pregnancy during the study.
Men who are sexually active with women who can have children must agree to use birth control while taking the study medication and for 7 months after the last dose. This is to prevent pregnancy during the study.
Both men and women can participate in the study.
The study includes people who are considered a vulnerable population, meaning they may need extra protection or care.

Who Cannot Join the Study?

Patients who have a different type of cancer other than Stage IV Non-Small Cell Lung Cancer (NSCLC) cannot participate. Stage IV means the cancer has spread to other parts of the body.
Patients who have not had their cancer confirmed by a test called a histological test cannot participate. This test checks the tissue under a microscope to confirm the type of cancer.
Patients who are not within the specified age range for the study cannot participate. The age range is not specified here, but it is important for eligibility.
Patients who are not part of the specified clinical trial group cannot participate. This group is not detailed here, but it is a requirement for the study.
Patients who are not male or female cannot participate, as the study includes both genders.
Patients who are considered part of a vulnerable population cannot participate. This term refers to groups who may need special protection, like children or those unable to give consent.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

Site Name	City	Country	Status
Hospital Universitario Y Politecnico La Fe	Valencia	Spain
Centre Hospitalier Universitaire De Lille	Lille	France

Other Sites

Site Name	City	Country
Centrum Onkologii Im. Prof. Franciszka Lukaszczyka W Bydgoszczy	Bydgoszcz	Poland
Robert Bosch Krankenhaus GmbH	Stuttgart	Germany
Asklepios Klinik Gauting GmbH	Gauting	Germany
Centre Hospitalier Lyon Sud	Pierre Benite	France
Hospital Universitario 12 De Octubre	Madrid	Spain
Algemeen Ziekenhuis Delta	Roeselare	Belgium
University Hospital Limerick	Limerick	Ireland
HELIOS Klinikum Emil von Behring GmbH	Berlin	Germany
LungenClinic Grosshansdorf GmbH	Grosshansdorf	Germany
Centrul De Oncologie SF Nectarie S.R.L.	Craiova	Romania
Centre Hospitalier Universitaire De Montpellier	Montpellier	France
Institute Of Oncology Prof. Dr. Ion Chiricuta Cluj-Napoca	Cluj Napoca	Romania
Centre Hospitalier Universitaire De Nantes	Nantes	France
Lungenklinik Hemer Deutscher Gemeinschafts-Diakonieverband GmbH	Hemer	Germany
Centre Hospitalier Universitaire De Caen Normandie	Caen	France
Cqreit Lexv Bzydbj	Lyon	France
Uzxomovbsadtse Cytognb Kpjbgljxk	Gdansk	Poland
Hphzenzz Vzxd denuincj	Barcelona	Spain
Hmsasgio Udyvrbhperaxf dk A Cppavc	A Coruna Galicia	Spain

Trial status

Country	Status	Recruitment Start
Belgium	Not recruiting	28.09.2017
France	Not recruiting	28.09.2017
Germany	Not recruiting	28.09.2017
Ireland	Not recruiting	28.09.2017
Poland	Not recruiting	28.09.2017
Romania	Not recruiting	28.09.2017
Spain	Not recruiting	28.09.2017

Trial locations

Investigated drugs:

Nivolumab is a medication used in this trial to help the immune system attack cancer cells. It works by blocking a protein that prevents the immune system from effectively targeting and destroying cancer cells.

Ipilimumab is another medication used in combination with nivolumab. It also helps the immune system fight cancer by blocking a different protein that can stop the immune system from working properly against cancer cells.

Chemotherapy is a standard cancer treatment that uses drugs to kill or stop the growth of cancer cells. In this trial, chemotherapy is used both alone and in combination with nivolumab and ipilimumab to treat patients with stage IV non-small cell lung cancer.

Investigated diseases:

Non-small cell lung cancer stage IV

Stage IV Non-Small Cell Lung Cancer (NSCLC) – This is an advanced form of lung cancer where the disease has spread beyond the lungs to other parts of the body. It originates from the epithelial cells lining the lungs and is characterized by uncontrolled cell growth. As the disease progresses, it can invade nearby tissues and organs, leading to symptoms such as persistent cough, chest pain, and difficulty breathing. The spread of cancer cells, known as metastasis, often affects the brain, bones, liver, and adrenal glands. This stage of NSCLC is typically diagnosed through imaging tests and biopsy, revealing the extent of the disease. The progression of Stage IV NSCLC can vary, with some patients experiencing rapid advancement while others may have a slower disease course.

Trial ID:

2023-508757-75-00

Protocol code:

CA209-9LA

NCT ID:

NCT03215706

Trial Phase:

Therapeutic confirmatory (Phase III)

Other Trials to Consider

#1 Clinical Trials Search in Europe

Study Comparing Nivolumab and Ipilimumab with Chemotherapy to Chemotherapy Alone for Patients with Stage IV Non-Small Cell Lung Cancer

What is this study about?

Who Can Join the Study?

Who Cannot Join the Study?